A detailed history of Ahrens Investment Partners LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Ahrens Investment Partners LLC holds 318 shares of EDIT stock, worth $416. This represents 0.0% of its overall portfolio holdings.

Number of Shares
318
Holding current value
$416
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 21, 2023

BUY
$7.03 - $11.53 $2,235 - $3,666
318 New
318 $2,000
Q2 2022

Aug 02, 2022

BUY
$9.99 - $21.35 $779 - $1,665
78 Added 24.76%
393 $5,000
Q1 2022

Apr 28, 2022

SELL
$14.08 - $27.63 $12,460 - $24,452
-885 Reduced 73.75%
315 $6,000
Q4 2021

Jan 21, 2022

BUY
$26.55 - $40.57 $31,860 - $48,684
1,200 New
1,200 $32,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Ahrens Investment Partners LLC Portfolio

Follow Ahrens Investment Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ahrens Investment Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ahrens Investment Partners LLC with notifications on news.